![]() |
|
|
Vol. 53, Issue 1, 112-122, January 1998
Division of Biochemistry, Walter Reed Army Institute of Research, Washington D. C. 20307-5100 (A.S., B.P.D.), Israel Institute for Biological Research, Ness-Ziona, Israel (Y.A., L.R.), and Oxford GlycoSciences Ltd., Abingdon, Oxon OX14 3YS, UK (D.S., T.P.)
| |
Summary |
|---|
|
|
|---|
To understand the role of glycosylation in the circulation of cholinesterases, we compared the mean residence time of five tissue-derived and two recombinant cholinesterases (injected intravenously in mice) with their oligosaccharide profiles. Monosaccharide composition analysis revealed differences in the total carbohydrate, galactose, and sialic acid contents. The molar ratio of sialic acid to galactose residues on tetrameric human serum butyrylcholinesterase, recombinant human butyrylcholinesterase, and recombinant mouse acetylcholinesterase was found to be ~1.0. For Torpedo californica acetylcholinesterase, monomeric and tetrameric fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase, this ratio was ~0.5. However, the circulatory stability of cholinesterases could not be correlated with the sialic acid-to-galactose ratio. Fractionation of the total pool of oligosaccharides obtained after neuraminidase digestion revealed one major oligosaccharide for human serum butyrylcholinesterase and three or four major oligosaccharides in other cholinesterases. The glycans of tetrameric forms of plasma cholinesterases (human serum butyrylcholinesterase, fetal bovine serum acetylcholinesterase, and equine serum butyrylcholinesterase) clearly demonstrated a reduced heterogeneity and higher maturity compared with glycans of monomeric fetal bovine serum acetylcholinesterase, dimeric tissue-derived T. californica acetylcholinesterase, and recombinant cholinesterases. T. californica acetylcholinesterase, recombinant cholinesterases, and monomeric fetal bovine serum acetylcholinesterase showed a distinctive shorter mean residence time (44-304 min) compared with tetrameric forms of plasma cholinesterases (1902-3206 min). Differences in the pharmacokinetic parameters of cholinesterases seem to be due to the combined effect of the molecular weight and charge- and size-based heterogeneity in glycans.
| |
Introduction |
|---|
|
|
|---|
ChEs
are serine esterases that catalyze the hydrolysis of choline esters.
The soluble plasma-derived ChEs from mammalian sources potentially can
be used as pretreatment drugs for OP toxicity (Ashani et
al., 1991
; Brandeis et al., 1993
; Broomfield et
al., 1991
; Maxwell et al., 1992
; Raveh et
al., 1989
, 1993
, 1997
; Wolfe et al., 1992
). Human BChE
can alleviate succinylcholine-induced apnea (Lockridge, 1990
) and may
be used to detoxify ester bond-containing environmental toxins such as
cocaine (Lockridge, 1990
; Mattes et al., 1996
). The
successful demonstration of plasma-derived ChEs as OP scavengers is
attributed to their ability to sequester rapidly a wide variety of OPs
and to their long residence time in circulation compared with ChEs of
nonplasma origin (Raveh et al., 1989
, 1993
, 1997
).
It has been suggested that the relatively high stability of the
globular tetrameric form of human plasma BChE may be associated with
capping of the terminal carbohydrate residues with sialic acid (Douchet
et al., 1982
). Kronman et al. (1995)
showed that the macroscopic rate constants for the clearance of various engineered glycoforms of recombinant human AChE from the circulation of mice could
be correlated with the number of unoccupied sialylation sites. It was
argued further that the enhanced stability of HuS BChE and FBS AChE is
due to an almost complete sialylation of the terminal glycan residues
on these enzymes. However, a recent report from our laboratory showed
that although sialylation was a key factor in maintaining FBS AChE and
Eq BChE in the circulation of mice for long periods, complete
sialylation of all galactose residues was not essential for extending
the circulatory life-time of these glycoproteins. The molar ratio of
sialic acid to galactose residues on FBS AChE and Eq BChE suggested
that only half of the galactose residues were capped with sialic acid,
yet these serum-derived ChEs displayed a mean residence time of ~20
hr in mice (Saxena et al., 1997
).
The disposition of glycoproteins in circulation is expected to be
influenced by the size, charge, shape, hydrophobicity, and number and
type of carbohydrate chains on the protein. A straightforward correlation between the structures of glycans and pharmacokinetic data
is complicated by the facts that the mechanism for the hepatic metabolism and renal clearance of ChEs is not established and there is
a substantial microheterogeneity in the oligosaccharides. To date, the
correlation between the structure of glycans and MRT has been made with
only FBS AChE and Eq BChE. Recombinant ChEs may be used to probe the
role of carbohydrates in the circulatory properties of the enzymes
(Kronman et al., 1995
). However, the glycan structure of
recombinant glycoproteins may be affected by the glycosylation site,
type of mutation, expression system, and cell culture conditions in use
(Goochee, 1992
). The number and characteristics of the oligosaccharides
on ChEs that are produced by methods of genetic engineering cannot be
fully predicted from the sequence of the protein. Therefore, a rigorous
structural analysis is required to understand the carbohydrate
determinants that control the circulatory stability of ChEs.
In a continued effort to understand the role of glycosylation in the clearance of exogenously administered ChEs, we have examined in mice the dependence of the Vss and MRT of five tissue-derived and two recombinant ChEs on the carbohydrates associated with these enzymes. The results provide for the first time the carbohydrate composition and oligosaccharide profiles of recombinant ChEs. The comparative pharmacokinetic study allowed us to examine the possible relationship among protein size, monosaccharide composition, fraction of acidic oligosaccharides, and circulatory stability of ChEs from diverse sources.
| |
Materials and Methods |
|---|
|
|
|---|
Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, 1985).
Electrophoretically pure AChE from FBS was purified as described
previously (De la Hoz et al., 1986
). The specific activity of this enzyme was 5600 units/mg. The monomeric and tetrameric forms of
FBS AChE were resolved by gel permeation chromatography of purified FBS
AChE on Biogel A 1.5-m column (1.5 × 170 cm) equilibrated with 50 mM sodium phosphate, pH 8.0. Purified BChE from human serum
(specific activity, 750 units/mg) and the dimeric form of AChE from
T. californica (specific activity, 2500 units/mg) were provided by Dr. Patrick Masson (Center de Recherches du Service de
Santé des Armées, La Tronche, France) and Dr. Israel Silman (Weizmann Institute, Rehovot, Israel), respectively. Recombinant Hu
BChE expressed in CHO cells was provided by Dr. Oksana Lockridge (University of Nebraska Medical Center, Omaha, NE). A soluble, monomeric form of rMo AChE truncated at its carboxyl-terminal end and
expressed in HEK 293 cells was provided by Dr. Palmer Taylor
(University of California at San Diego, La Jolla, CA). The specific
activity of purified rHu BChE was 600 units/mg and that of rMo AChE was
1850 units/mg.
Release, isolation, labeling, and profile analysis of carbohydrates were performed by Oxford GlycoSciences according to the procedures described below:
Monosaccharide Composition Analysis of ChEs.
The
oligosaccharides associated with various ChEs were released
quantitatively and recovered by automated hydrazinolysis (GlycoPrep 1000; Oxford GlycoSciences) as described previously (Saxena et al., 1997
). Samples of ChEs containing 0.15 mg of protein were subjected to exhaustive microflow dialysis against 0.1% (v/v) trifluoroacetic acid using a BRL (Natick, MA) 1200 MA apparatus with
5-10-kKDa cutoff dialysis membrane. Each sample was then transferred
to a reaction vessel using 0.1% (v/v) trifluoroacetic acid, followed
by lyophilization (<50 mTorr, >24 hr), and the oligosaccharides were
released and recovered using the "N + O" program (GlycoPrep; Oxford
Glycosciences). As controls, an aliquot of a standard monosaccharide
mixture and a reagent "blank" were simultaneously analyzed.
Charge-Distribution Analysis of the Total Pool of
Oligosaccharides Released from ChEs.
The oligosaccharides released
from various ChEs (400 µg) by automated hydrazinolysis were labeled
with 2-AB according to the standard procedure used by Oxford
GlycoSciences (Bigge et al., 1995
). The samples were applied
to Whatman (Clifton, NJ) 3MM chromatography paper and subjected to
ascending paper chromatography at ambient temperature for 30 min using
1-butanol/ethanol/water (4:1:1) as the solvent. The labeled sample
remaining at the origin was eluted with water. Carbohydrates of
disaccharide or larger size did not move in this solvent system under
these conditions. This procedure lead to the quantitative and
nonselective recovery of the total pool of oligosaccharides associated
with the ChEs as 2-AB-labeled oligosaccharides.
Size-Distribution Analysis of the Total Pool of Deacidified
Oligosaccharides Released from ChEs.
An aliquot of the total pool
of deacidified 2-AB-labeled oligosaccharides was mixed with an aqueous
solution of a partial acid hydrolysate of dextran and subjected to high
resolution gel permeation chromatography using the RAAM 2000. Water was
used as the eluant at 55° at a constant flow rate of 80 µl/min over 10.6 hr. The eluate from the column was monitored using an in-line fluorescence flow detector to detect fluorescent glycans, as well as an
in-line differential refractometer to detect individual glucose
oligomers. The hydrodynamic volumes of individual 2-AB- labeled
oligosaccharides were determined from their elution position in
reference to the glucose oligomers. The conjugation of glycans with
2-AB decreases their hydrodynamic volume by a constant value, and the
hydrodynamic volume of the 2-AB-conjugated form of glycan can be
correlated with that of the alditol form using the following relationship (Bigge et al., 1995
): Hydrodynamic volume of
2-AB form = (1.02 × hydrodynamic volume of alditol)
2.65.
Sucrose Density Gradient Sedimentation Analysis of the Molecular
Forms of ChEs.
Aliquots of various ChEs (5 units/100 µl) were
mixed with catalase (11.3S, used as a sedimentation marker) and applied
to linear 5-20% sucrose gradients prepared in 50 mM
sodium phosphate, pH 8.0. The gradients were centrifuged at 75,000 × g for 18 hr at 4° in an SW41Ti rotor (Beckman
Instruments, Fullerton, CA). Gradients were fractionated from the top
using an AutoDensiflow IIC (Buchler Instruments, Lenexa, KS), and
fractions were assayed for AChE activity using the micro-Ellman assay
(Doctor et al., 1987
).
Pharmacokinetic Studies.
The experiments were carried out as
described previously (Raveh et al. 1993
). All enzyme samples
were exhaustively dialyzed against sterile phosphate-buffered saline,
pH 7.4. Each enzyme (39-320 units in a volume of 0.1-0.2 ml) was
administered intravenously into the tail vein of Balb/c male mice
(22-36 g each). These doses were sufficient to increase the plasma
concentration of ChEs well above the level of endogenous ChE. At
various time intervals, heparinized blood samples (5-10 µl) were
withdrawn from the retro-orbital sinus of mice and diluted 21-fold in
distilled water at 4°. ChE activity was determined using
acetylthiocholine or butyrylthiocholine as the substrate for AChE or
BChE, respectively, using the assay of Ellman et al. (1961)
.
Endogenous ChE activity was subtracted from the result. The activity
was normalized to plasma volume assuming that it constituted 55% of
the whole blood volume.
|
(1) |
In Vitro Stability of ChEs in Mouse Blood.
Stock solutions of various ChEs were diluted in mouse blood collected
above heparin to a final concentration of 13-27 units/ml and incubated
at 37°. Any changes in enzyme activity with time were monitored using
the Ellman assay, as described above (Ellman et al., 1961
).
| |
Results |
|---|
|
|
|---|
Monosaccharide Composition Analysis. To determine the type of carbohydrate units that were present in various ChEs, enzymes were subjected to monosaccharide composition analysis. HuS BChE contained the greatest amount of carbohydrate (31% by weight of protein) compared with other plasma-derived ChEs, such as tFBS AChE and Eq BChE, which contained 9% and 23% carbohydrate by weight, respectively (13). T. californica AChE, mFBS AChE, rMo AChE, and rHu BChE contained 9%, 9%, 10%, and 13% carbohydrate by weight of protein, respectively (Table 1). Of the total monosaccharides present in all ChEs, 33-40% was present as N-acetylglucosamine and 21-31% were present as mannose. All ChEs contained 18-21% carbohydrate in the form of galactose except T. californica AChE, which contained only 8% galactose. HuS BChE, rMo AChE, and rHu BChE contained 15-18% of monosaccharides as sialic acid, whereas mFBS AChE (10.8%) and T. californica AChE (4.9%) were significantly undersialylated. The molar ratio of sialic acid to galactose residues on HuS BChE, rHu BChE, and rMo AChE was found to be ~1.0. For T. californica AChE, mFBS and tFBS AChE, and Eq BChE, this ratio was ~0.5. As shown in Table 2, the total number of complex carbohydrate chains/subunit calculated from their mannose content was 12 for HuS BChE, 4 for T. californica AChE, 3 for mFBS AChE, 3 for rMo AChE, and 5 for rHu BChE.
|
|
Nature of N-Linked Oligosaccharides of ChEs.
Charge-based separation of the 2-AB-labeled oligosaccharides associated
with various ChEs was performed using anion exchange high performance
liquid chromatography on a GlycoSep C column. The resulting
chromatograms are shown in Fig. 1, A, C,
E, G, and I. The oligosaccharides associated with all ChEs consist of
neutral as well as acidic components. The relative content of neutral and acidic oligosaccharides for various ChEs is listed in Table 2. HuS
BChE contained 84% acidic oligosaccharides, similar to the value of
81% reported previously for Eq BChE (Saxena et al., 1997
).
The two recombinant ChEs contained 60-70% acidic oligosaccharides. In
contrast, the other two tissue-derived AChEs, T. californica AChE and mFBS AChE, contained only 30-40% acidic oligosaccharides. To
determine the nature of the acidic substituents, an aliquot of the
2-AB-labeled oligosaccharides (20-50 µM) was digested
exhaustively with neuraminidase from A. ureafaciens, which
cleaves
2-3(6) bonds, and then analyzed by GlycoSep C
chromatography. The resulting chromatograms are shown in Fig. 1, B, D,
F, H, and J. No acidic oligosaccharides were detectable after
neuraminidase treatment. Therefore, in both cases, the acidic
substituent on the oligosaccharide chain was a covalently linked
nonreducing, terminal outer-arm sialic acid residue. These results are
in agreement with previous findings with FBS AChE and Eq BChE (Saxena
et al., 1997
). The minor peak in Fig. 1, B and H, is due to
the separation of low-molecular-weight glycans from the major
oligosaccharide pool.
|
|
Sucrose Density Centrifugation Analysis. The molecular forms of various ChEs used in this study were determined by sucrose density gradient centrifugation analysis shown in Fig. 3. As shown in Fig. 3, A and C, HuS BChE and FBS AChE, the two ChEs derived from plasma sources were tetramers, T. californica AChE was dimeric in form (Fig. 3E), and mFBS AChE is shown in Fig. 3D. Of the two recombinant ChEs tested, rHu BChE was a mixture of monomers, dimers, and tetramers (Fig. 3B), whereas rMo AChE was in monomeric form only (Fig. 3F).
|
Pharmacokinetic Studies. After intravenous injection, plasma activity of all ChEs declined in two phases, and curve fitting was carried out in accordance with the equation (Fig. 4). The time course profiles show that tFBS AChE had a longer half-life than mFBS AChE and that tetrameric native HuS BChE had a longer half-life than rHu BChE. Results from seven ChEs examined in Balb/c mice, including tFBS AChE and Eq BChE, did not reveal any clear-cut relationship between the coefficients A0 and B0 and the number, composition, or charge of the glycan chains on ChEs (not shown).
|
|
|
In Vitro Stability of ChEs in Mouse Blood. No significant inactivation of Eq BChE, HuS BChE, tFBS AChE, and rMo AChE was detected after a 24-hr incubation of these enzymes in mouse blood at 37°. mFBS AChE, T. californica AChE, and rHu BChE were less stable and lost 30-50% of the original activity within 24 hr. Due to the rapid clearance of these enzymes, the apparent blood-induced inactivation did not significantly affect interpretation of the pharmacokinetic data. However, it suggests that the carbohydrates may control in part the susceptibility of ChEs to proteolytic degradation.
| |
Discussion |
|---|
|
|
|---|
The successful application of native and recombinant ChEs as
detoxifying drugs largely depends on their ability to remain at
therapeutic plasma levels for prolonged periods. The aim of this study
was to highlight the structural features of ChEs that may determine the
circulatory fate of these enzymes. The integrity of the oligosaccharide
chains on native ChEs has been demonstrated to be essential for
maintaining enzyme activity in circulation (Douchet et al.,
1982
; Saxena et al., 1997
). Therefore, we attempted to
elucidate the structural/functional relationship between the carbohydrates and the pharmacokinetic behavior of ChEs. Two major questions were addressed: Does the ratio of sialic acid to galactose correlate with the pharmacokinetics of ChEs? To what extent can the
major differences in the glycan composition be correlated with the
volume of distribution and the total body MRT of ChEs in mice? The
availability of a variety of ChEs also permitted an analysis of the
relationship between subunit organization and the disposition behavior
of the enzyme.
Monosaccharide composition analysis revealed differences in the total
carbohydrate, galactose, and sialic acid contents of various ChEs. The
relatively high content of mannose suggested the presence of
N-linked oligosaccharides, and the presence of N-acetylgalactosamine indicated the presence of
O-linked oligosaccharides in the ChEs examined. It seems
that recombinant ChEs possess a higher amount of O-linked
oligosaccharides than tissue-derived ChEs. Although the presence of
N-linked carbohydrates in AChEs is well established (Heider
et al., 1991
; Liao et al., 1992
, 1993
), the
presence of O-linked carbohydrates has been described only on the globular form of AChE from rat neuromuscular junction (Scott and
Sanes, 1984
) and AChE from various compartments of bovine chromaffin
cells (Bon et al., 1990
). The presence of galactose indicated that the majority of glycans in all ChEs except T. californica AChE were of the complex or hybrid type rather than
the high-mannose type. In addition, substantial amounts of the
oligosaccharides in all ChEs except Eq BChE were fucosylated (Saxena
et al., 1997
).
On the basis of the amino acid sequences reported for various ChEs,
nine N-glycosylation sites for human BChE (Lockridge
et al., 1987
), four potential N-glycosylation
sites for T. californica AChE (Schumacher et al.,
1986
), five sites for FBS AChE (Doctor et al., 1990
), and
three sites for rMo AChE (Rachinsky et al., 1990
) have been
identified. The number of N-glycosylation sites for HuS BChE
(12) and Eq BChE (11), as calculated on the basis of mannose content,
is greater than the number predicted from the sequence. This result
suggests that in addition to complex oligosaccharides, these enzymes
contain high-mannose oligosaccharides. The number of
N-glycosylation sites of three for mFBS AChE is in agreement
with the number calculated on the basis of the mannose content for tFBS
AChE (Saxena et al., 1997
).
The molar ratio of sialic acid to galactose residues on HuS BChE, rMo
AChE, and rHu BChE was ~1.0, suggesting that all the terminal
galactose residues were capped with sialic acid. However, the MRT of
HuS BChE was 9- and 14-fold greater than that of rMo AChE and rHu BChE,
suggesting that the capping of galactose with sialic acid by itself is
not sufficient to confer circulatory stability to ChEs. For T. californica AChE (MRT, 44 min) and mFBS AChE (MRT, 304 min), this
ratio was ~0.5, suggesting that only half of the terminal galactose
residues were capped with sialic acid, yet these enzymes differed
greatly in their circulatory stability. In contrast, a molar ratio of
0.5 for sialic acid to galactose was previously observed for the highly
stable tFBS AChE and Eq BChE (Saxena et al., 1997
). The lack
of a correlation between the sialic acid-to-galactose ratio and MRT
also was reported for human IgM monoclonal antibodies (Maiorella
et al., 1993
). These observations substantiate the previous
suggestion that although the presence of sialic acid seems to be
essential for maintaining ChEs in circulation, the location rather than
the number of the nonsialylated galactose residues may be affecting
circulatory stability (Saxena et al., 1997
).
Differences in oligosaccharides of ChEs from various sources and the
microheterogeneity in glycans on each ChE were elucidated by charge-
and size-based separation analyses. Anion exchange chromatography of
the oligosaccharide pools suggested that these ChEs differ
substantially in the amount of negatively charged glycans they carry.
Fractionation of the total pool of desialylated oligosaccharides on the
basis of their effective hydrodynamic volume revealed only one major
oligosaccharide for HuS BChE. This result is in agreement with previous
studies in which one major component for HuS BChE at 11.2 gu (13.5 gu
for the alditol) and for Eq BChE at 11.3 gu (13.6 gu for the alditol)
was identified. The structure of this glycan was determined to be of
the complex biantennary type (Ohkura et al., 1994
; Saxena
et al., 1997
). The elution position of the oligosaccharide
for HuS BChE suggests that its structure may be of the complex
biantennary type. The two major oligosaccharides for tFBS AChE also
were found to be of the complex biantennary type (Saxena et
al., 1997
).
In contrast, size-based fractionation of the desialylated
oligosaccharide pools yielded three or four major oligosaccharides for
T. californica AChE, mFBS AChE, rMo AChE, and rHu BChE. The glycans eluting at 11.2 and 12.2 gu are most likely of the complex biantennary type (Saxena et al., 1997
), and the other peaks
probably correspond to high-mannose, hybrid triantennary and
tetra-antennary structures. This conclusion was arrived at by combining
the information obtained from the elution profiles with the
galactose-to-mannose and N-acetylglucosamine-to-mannose
ratios for various ChEs. For example, the galactose-to-mannose (0.64)
and N-acetylglucosamine-to-mannose (1.37) ratios observed
for Eq BChE are consistent with the presence of predominantly complex
biantennary type of structures in this enzyme (Saxena et
al., 1997
). An increase in the galactose-to-mannose (0.78-0.83) and N-acetylglucosamine-to-mannose
(1.43-1.56) ratios suggest that in addition to complex
biantennary complex type of structures, HuS BChE, mFBS AChE, rMo AChE,
and rHu BChE contain triantennary and tetra-antennary structures. The
galactose-to-mannose ratio is even higher for mFBS AChE (0.87),
probably due to the presence of glycans containing the galactose
1-3 galactose
1-4 determinant that was recently identified in
tFBS AChE (Saxena et al., 1997
). The galactose-to-mannose
(0.26) and N-acetylglucosamine-to-mannose (1.27) ratios for
T. californica AChE suggest the presence of high-mannose
glycans in this enzyme.
Differences in the oligosaccharide profiles of HuS BChE and rHu BChE
are consistent with observations made with the recombinant forms of
tissue plasminogen activator and erythropoietin expressed in different
cell lines, which showed that a polypeptide expressed in cell types
other than that in which it is normally expressed differs from the
native glycoprotein with respect to the structure of certain
oligosaccharides, as well as the relative amounts of common
oligosaccharides (Parekh et al., 1989
; Takeuchi et
al., 1989
). In another study, a human monoclonal IgM antibody
produced by ascites culture possessed a 80-100-fold greater MRT in
rats compared with that produced by in vitro culture methods
(Gauny et al., 1991
; Maiorella et al., 1993
).
Therefore, it seems that the structure and microheterogeneity in the
oligosaccharide chains on ChEs may be species and cell type specific
and may depend on the culture conditions being used for expressing
recombinant ChEs.
No unambiguous correlation could be made between pharmacokinetic parameters and monosaccharide composition or the amount of nonsialylated galactose residues. The apparent Vss after equilibrium was achieved, and the total body MRT seemed to depend on subunit organization and the negative charge donated by the sialic acid residues. For high-molecular-weight proteins, the extravascular distribution is expected to be very low. Indeed, variations in Vss were relatively small, compared with Vp, and rapidly reached a limiting value with the dimeric form of T. californica AChE. The increase in Vss could be a result of the binding of ChEs to the endothelial capillary walls, due to the charged oligosaccharides, and/or their distribution in the extravascular spaces. Regardless of the rate of elimination, the larger Vss for mFBS AChE, rMo AChE, and rHu BChE compared with the tetrameric forms of plasma ChEs requires a higher dose of these enzymes to achieve the same plasma concentration of all ChEs. On the whole, Vss did not increase >2-fold over the Vp value, and it seemed to be enhanced by the presence of negatively charged glycans.
To examine possible combinatorial influences of the molecular size and
charge on the circulatory stability of ChEs, a three-dimensional graph
was constructed from the plot of MRT on a molecular weight/percent acidic fraction grid (Fig. 6). The graph
includes data for desialylated tFBS AChE and Eq BChE, which maintained
their catalytic activity and subunit assembly intact (Saxena et
al., 1997
). Inspection of the graph suggests the following: (1)
the removal of sialic acid was accompanied with a substantial decrease
in MRT of tFBS AChE and Eq BChE; (2) because the subunit organization
remained unchanged, the enhanced clearance does not seem to be caused
by renal excretion but seems to be due to accelerated hepatic
metabolism; and (3) mFBS AChE possesses a much shorter MRT than tFBS
AChE. Because the two enzymes carry the same number of charged
oligosaccharides and a similar monosaccharide composition, the presence
of size heterogeneity in glycans (Fig. 2) did not permit a clear-cut
conclusion regarding the effect of subunit assembly on the circulatory
life-time of FBS AChE. Similarly, comparison of HuS BChE and rHu BChE
shows that the former is tetrameric in form, whereas the latter
consists of predominantly monomers and dimers and some tetramers. In
both enzymes, the galactose residues seem to be completely capped with sialic acid, and they contain mostly acidic oligosaccharides. Although
the MRT of HuS BChE is 14-fold greater than that of rHu BChE, the
observation that the former enzyme contains one major oligosaccharide
and rHu BChE contains at least four major oligosaccharides precludes
definite conclusions regarding the contribution of the quaternary
structure to the circulatory stability of ChEs.
|
The in vitro data on the stability of ChEs in mouse blood
raise the possibility that the variability in glycan chains may influence the resistance of these enzymes to proteolytic degradation. It has been suggested that large N-glycans may prevent the
proteolysis of the extracellular domain of human erythrocyte CD59 (Rudd
et al., 1997
). It is possible that the mature
N-glycans of plasma ChEs at specific sites may be protecting
them from proteases in vivo, contributing to their
circulatory stability.
In conclusion, the results presented here reveal differences in the
oligosaccharides of native and recombinant ChEs with regard to the
total carbohydrate content and charge- and size-based oligosaccharide profiles. However, neither the carbohydrate composition nor the oligosaccharide profile could be completely correlated with the pharmacokinetic parameters of these enzymes. Although the correlation between glycan characteristics and pharmacokinetic parameters is not
fully understood, it is noteworthy that the glycans of recombinant ChEs
and mFBS AChE displayed a remarkable heterogeneity in size and consist
of hybrid and complex biantennary, triantennary, and tetra-antennary
structures. T. californica AChE also contains high-mannose
structures. The three plasma ChEs, on the other hand, contain mature
glycans that are predominantly of the complex biantennary type,
confirming that these structures are responsible for the extended MRTs
of the enzymes. The possible clearance of ChEs from the circulation of
animals via galactose receptors (Ashwell and Morell, 1974
; Ashford and
Harford, 1982), fucose/N-acetylglucosamine receptors
(Lehrman et al., 1986
), and/or mannose receptors (Day et al., 1980
) emphasizes the need for determining the
structures of the individual glycans. Thus, the site-specific analysis
of glycan structures may elucidate the structures responsible for the
rapid clearance of nonplasma ChEs and clarify the mechanism for the
uptake of ChEs from the circulation of animals.
| |
Acknowledgments |
|---|
The authors are grateful to Dr. Israel Silman (Weizmann Institute, Rehovot, Israel) for the gift of purified T. californica AChE, Dr. Patrick Masson (Center de Recherches du Service de Santé des Armées, La Tronche, France) for the gift of purified human serum BChE, Dr. Oksana Lockridge (University of Nebraska Medical Center, Omaha, NE) for the gift of purified recombinant human BChE, and Dr. Palmer Taylor (University of California at San Diego, La Jolla, CA) for the gift of purified recombinant mouse AChE. We thank Deborah Moorad for running sucrose gradients.
| |
Footnotes |
|---|
Received July 23, 1997; Accepted September 15, 1997
Send reprint requests to: Dr. Ashima Saxena, Division of Biochemistry, Walter Reed Army Institute of Research, 14th & Dahlia Street N.W., Washington, DC 20307-5100.
| |
Abbreviations |
|---|
ChE, cholinesterase; AChE, acetylcholinesterase; BChE, butyrylcholinesterase; FBS, fetal bovine serum; mFBS AChE, monomeric fetal bovine serum acetylcholinesterase; tFBS AChE, tetrameric fetal bovine serum acetylcholinesterase; Eq, equine (serum); HuS, human serum; rHu, recombinant human; rMo, recombinant mouse; OP, organophosphate; TMS, trimethylsilyl; 2-AB, 2-aminobenzamide; gu, glucose units; MRT, mean residence time; Vp, plasma volume; Vss, volume of distribution at steady state; CL, total body clearance; kel, elimination rate constant.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
O. Cohen, C. Kronman, A. Lazar, B. Velan, and A. Shafferman Controlled Concealment of Exposed Clearance and Immunogenic Domains by Site-specific Polyethylene Glycol Attachment to Acetylcholinesterase Hypolysine Mutants J. Biol. Chem., December 7, 2007; 282(49): 35491 - 35501. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Evron, B. C. Geyer, I. Cherni, M. Muralidharan, J. Kilbourne, S. P. Fletcher, H. Soreq, and T. S. Mor Plant-derived human acetylcholinesterase-R provides protection from lethal organophosphate poisoning and its chronic aftermath FASEB J, September 1, 2007; 21(11): 2961 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Huang, Y. Huang, H. Baldassarre, B. Wang, A. Lazaris, M. Leduc, A. S. Bilodeau, A. Bellemare, M. Cote, P. Herskovits, et al. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning PNAS, August 21, 2007; 104(34): 13603 - 13608. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Cohen, C. Kronman, L. Raveh, O. Mazor, A. Ordentlich, and A. Shafferman Comparison of Polyethylene Glycol-Conjugated Recombinant Human Acetylcholinesterase and Serum Human Butyrylcholinesterase as Bioscavengers of Organophosphate Compounds Mol. Pharmacol., September 1, 2006; 70(3): 1121 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gao, E. Atanasova, N. Sui, J. D. Pancook, J. D. Watkins, and S. Brimijoin Gene Transfer of Cocaine Hydrolase Suppresses Cardiovascular Responses to Cocaine in Rats Mol. Pharmacol., January 1, 2005; 67(1): 204 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sun, M. L. Shen, Y.-P. Pang, O. Lockridge, and S. Brimijoin Cocaine Metabolism Accelerated by a Re-Engineered Human Butyrylcholinesterase J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 710 - 716. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Duysen, C. F. Bartels, and O. Lockridge Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine Toxicity J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 751 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Koetzner and J. H. Woods Characterization of Equin |